Ideal number of target lesions per organ to measure in metastatic colorectal cancer.

Hyeong Su Kim,Jung Han Kim

doi:10.3892/ol.2014.2409

Hyeong Su Kim, Jung Han Kim

Open Access

https://doi.org/10.3892/ol.2014.2409

Copy DOI

Abstract

The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guideline states that the two largest lesions per organ should be measured as target lesions for assessment of the tumor response. This criterion is considered to be arbitrary and, to the best of our knowledge, has not been supported by any objective evidence. The present study hypothesized that measuring the single largest lesion in each organ into which the cancer had metastasized (termed the modified RECIST; mRECIST 1.1) may yield the same response classification as measuring the two target lesions per organ (as per the RECIST 1.1 guideline). The medical records of patients with metastatic colorectal cancer (CRC), who received first-line chemotherapy between January 2004 and June 2013 were reviewed. The tumor responses of the patients were compared according to the two criteria using computed tomography. A total of 38 patients were included in the present study, all of whom had at least two target lesions in any one organ according to the RECIST 1.1 guidelines. When adopting the mRECIST 1.1, rather than the RECIST 1.1, 18 patients (47.4%) demonstrated an increase in the rate of change of the sum of the tumor measurements. The overall response rates of chemotherapy were 39.4% and 34.2% according to the RECIST 1.1 and the mRECIST 1.1, respectively, and the difference between the two criteria was not identified to be significantly different (P=0.226). The tumor response showed near perfect agreement between the RECIST 1.1 and mRECIST 1.1 criteria (κ=0.905). Only two patients (5.3%) showed a disagreement with regard to the tumor responses between the two criteria. Therefore, it was identified that the mRECIST 1.1 showed a high level of concordance with the original RECIST 1.1 guidelines in the tumor response assessment of metastatic CRC patients to chemotherapy. The present results indicate that the mRECIST 1.1, with a decreased number of target lesions to be measured, may be more convenient in clinical practice for the assessment of tumor response.

Highlights

The accurate assessment of changes in tumor burden is critical for anticancer treatment as well as clinical trials of new drugs
The present results indicate that the modified RECIST (mRECIST) 1.1, with a decreased number of target lesions to be measured, may be more convenient in clinical practice for the assessment of tumor response
The present study investigated the impact of measuring the single largest lesion in each organ with metastatic disease, compared with measuring two target lesions per organ, as recommended by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, on the tumor response in patients with metastatic colorectal cancer (CRC)

Summary

Introduction

The accurate assessment of changes in tumor burden is critical for anticancer treatment as well as clinical trials of new drugs. Tumor sizes have been measured bi‐dimensionally by obtaining the product of the longest diameter and the longest perpendicular diameter of each tumor. In the early 1980s, the World Health Organization (WHO) developed the WHO response criteria in an attempt to standardize the methods for evaluating the tumor response [1]. As the details for selecting and measuring the target lesions were not clearly described in the WHO guidelines, the assessment of the tumor response has not been accurately reproducible between studies [2]. Major features of the RECIST 1.0 guideline included the use of unidimensional measures, rather than the bi‐dimensional measures previously recommended by WHO, for the evaluation of tumor size and instructions on the number of target lesions to be evaluated. The RECIST 1.0 guideline has been widely accepted as a standardized method for the assessment of the tumor response. A number of questions and issues regarding the number of target lesions, the size of lymph nodes (LNs) to be assessed and the utility of novel imaging technologies have been raised with regard to the RECIST 1.0 guidelines [4,5]

Methods

Results

Conclusion